Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Dose Ascending Study to Evaluate the Safety and Tolerability of the Therapeutic Radiopharmaceutical 131I-MIP-1095 for the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Conditions
Interventions
131I-MIP-1095
Locations
1
United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Start Date
January 19, 2017
Primary Completion Date
April 2, 2019
Completion Date
April 2, 2019
Last Updated
April 5, 2019
NCT06594926
NCT07177937
NCT06844383
NCT06926283
NCT06487507
NCT05919264
Lead Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions